Transition to mania during treatment of bipolar depression.
Some individuals with bipolar disorder transition directly from major depressive episodes to manic, hypomanic, or mixed states during treatment, even in the absence of antidepressant treatment. Prevalence and risk factors associated with such transitions in clinical populations are not well established, and were examined in the Systematic Treatment Enhancement Program for Bipolar Disorder study, a longitudinal cohort study. Survival analysis was used to examine time to transition to mania, hypomania, or mixed state among 2166 bipolar I and II individuals in a major depressive episode. Cox regression was used to examine baseline clinical and sociodemographic features associated with hazard for such a direct transition. These features were also examined for interactive effects with antidepressant treatment. In total, 461/2166 subjects in a major depressive episode (21.3%) transitioned to a manic/hypomanic or mixed state before remission, including 289/1475 (19.6%) of those treated with antidepressants during the episode. Among the clinical features associated with greatest transition hazard were greater number of past depressive episodes, recent or lifetime rapid cycling, alcohol use disorder, previous suicide attempt, and history of switch while treated with antidepressants. Greater manic symptom severity was also associated with risk for manic transition among both antidepressant-treated and antidepressant-untreated individuals. Three features, history of suicide attempt, younger onset age, and bipolar subtype, exhibited differential effects between individuals treated with antidepressants and those who were not. These results indicate that certain clinical features may be associated with greater risk of transition from depression to manic or mixed states, but the majority of them are not specific to antidepressant-treated patients.
Perlis
Roy H
RH
Department of Psychiatry, Bipolar Clinic and Research Program, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. rperlis@partners.org
Ostacher
Michael J
MJ
Goldberg
Joseph F
JF
Miklowitz
David J
DJ
Friedman
Edward
E
Calabrese
Joseph
J
Thase
Michael E
ME
Sachs
Gary S
GS
D000928:Antidepressive Agents / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000453:epidemiology / Q000523:psychology*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D008297:Male; D015995:Prevalence; D012307:Risk Factors; D016019:Survival Analysis
D000928:Antidepressive Agents
Arch Gen Psychiatry. 1979 May;36(5):555-9
435015
J Clin Psychiatry. 2008 Oct;69(10):1589-601
19192442
J Nerv Ment Dis. 1993 Apr;181(4):238-45
8097229
Bipolar Disord. 2009 Jun;11(4):391-400
19500092
Br J Psychiatry. 1979 Apr;134:382-9
444788
Arch Gen Psychiatry. 1972 Sep;27(3):304-9
4340658
Bipolar Disord. 2002 Oct;4(5):323-7
12479665
J Clin Psychiatry. 2004 Nov;65(11):1537-45
15554769
Bipolar Disord. 2004 Aug;6(4):333-7
15225153
Eur Neuropsychopharmacol. 1999 Aug;9 Suppl 4:S109-12
10524836
N Engl J Med. 2007 Apr 26;356(17):1711-22
17392295
Am J Psychiatry. 2006 Feb;163(2):232-9
16449476
Arch Gen Psychiatry. 2003 Nov;60(11):1079-88
14609883
Bipolar Disord. 2009 Aug;11(5):453-73
19624385
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
9881538
Am J Psychiatry. 1987 Nov;144(11):1403-11
3314536
Br J Psychiatry. 1978 Nov;133:429-35
728692
Am J Psychiatry. 2006 Feb;163(2):217-24
16449474
Am J Psychiatry. 2007 Sep;164(9):1348-55
17728419
Am J Psychiatry. 2001 Jun;158(6):906-12
11384898
Am J Psychiatry. 1988 Feb;145(2):179-84
3341463
Am J Psychiatry. 2006 Feb;163(2):313-5
16449487
Lancet. 1970 May 16;1(7655):1022-7
4191630
Am J Psychiatry. 2009 Feb;166(2):164-72
19015231
Psychopharmacol Bull. 2007;40(3):72-84
18007570
J Clin Psychiatry. 2005 May;66(5):611-6
15889948
Biol Psychiatry. 2003 Jun 1;53(11):1028-42
12788248
Am J Psychiatry. 2010 Mar;167(3):289-97
20008948
Prog Neuropsychopharmacol Biol Psychiatry. 2003 Aug;27(5):751-7
12921905